News
VP, Product, Qinecsa Solutions ...
Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...
In this video interview, Michel van Harten, MD, CEO, myTomorrows, discusses how patient education and remote monitoring can help with reducing the burden of trial participation.
Digital intake must be the default to ensure quality and efficiency: Prioritizing digital-first adverse event intake—tailored to the reporter's persona—improves data quality and reduces delays.
One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...
In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights how artificial intelligence can be used to address logistical barriers such as access and treatment cost.
Data from the FIBRONEER-IPF and FIBRONEER-ILD studies, published in The New England Journal of Medicine, highlight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback